Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Comparison Between 5-azacytidine Treatment and 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability
Authors not listed
Universitätsklinikum Hamburg-Eppendorf · 2011
Abstract
5-azacytidine treatment prolongs survival in patients with myelodysplastic syndrome (MDS), but does not cure the disease. Allogeneic stem cell transplantation is a curative treatment option but is associated with a high risk treatment-related morbidity and mortality. In the current trial allogeneic stem cell transplantation will be compared to 5-azacytidine only treatment according to donor availability in elderly patients with MDS (55-70 years).
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-13 MST
Cite this
APA
Anonymous. (2011). Comparison Between 5-azacytidine Treatment and 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability. <em>Universitätsklinikum Hamburg-Eppendorf</em>. https://clinicaltrials.gov/study/NCT01404741
Vancouver
Anonymous. Comparison Between 5-azacytidine Treatment and 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability. Universitätsklinikum Hamburg-Eppendorf. 2011.
BibTeX
@misc{anon2011Compar,
title = {Comparison Between 5-azacytidine Treatment and 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability},
author = {Anonymous},
journal = {Universitätsklinikum Hamburg-Eppendorf},
year = {2011},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Peking University People's Hospital 2026
Open access · US-GOV
Geriatric Assessment (GA) for Elderly Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: a Prospective Study.
Peking University People's Hospital 2018
Open access · US-GOV
Reduced Intensity Conditioning Regimen for Elderly or High Comorbidity Burden Patients Receiving Haploidentical Hematopoietic Stem Cell Transplantation
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 2019
Open access · US-GOV
Up-front Hematopoietic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia Aged 65-75
Longeveron Inc. 2014
Open access · US-GOV
A Phase I/II, Randomized, Blinded and Placebo-controlled Trial to Evaluate the Safety and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion in Patients With Aging Frailty
The First Affiliated Hospital of Soochow University 2026
Open access · US-GOV
A Single-arm, Prospective Study of a Cladribine-Bridged Lisaftolax and Busulfan Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory Myelodysplastic Syndromes and Acute Myeloid Leukemia in Elderly Patients
Assistance Publique - Hôpitaux de Paris 2023
Open access · US-GOV